Renaissance Capital logo

MaxCyte Priced, Nasdaq: MXCT

Provides cell engineering devices and services.

Industry: Health Care

Latest Trade: $10.43 -0.51 (-4.7%)

First Day Return: +30.8%

Return from IPO: -15.8%

Industry: Health Care

We believe in the vast potential of next-generation cell therapies to have a meaningful impact on the millions of patients worldwide who, despite medical advancement, live with unmet medical needs across a variety of diseases. Our aim is to be the premier cell engineering platform technology to support the development of advanced therapeutics. We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.
more less
IPO News for MaxCyte
more
IPO Data
IPO File Date 07/09/2021
Offer Price $13.00
Price Range $11.50 - $13.50
Offer Shares (mm) 13.5
Deal Size ($mm) $176
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/29/2021
Offer Price $13.00
Price Range $11.50 - $13.50
Offer Shares (mm) 13.5
Deal Size ($mm) $176
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Gaithersburg, MD
Founded 1998
Employees 65
Website www.maxcyte.com